The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
ER-targeted therapeutics provide valuable treatment options for patients with ER+ breast cancer, however, current relapse and mortality rates emphasize the need for improved therapeutic strategies. The recent discovery of prevalent ESR1 mutations in relapsed tumors underscores a sustained reliance of advanced tumors on ERα signaling, and provides a strong rationale for continued targeting of ERα. Here we describe GDC-0810, a novel, non-steroidal, orally bioavailable selective ER downregulator (SERD), which was identified by prospectively optimizing ERα degradation, antagonism and pharmacokinetic properties. GDC-0810 induces a distinct ERα conformation, relative to that induced by currently approved therapeutics, suggesting a unique mechanism of action. GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERα mutations. GDC-0810 is currently being evaluated in Phase II clinical studies in women with ER+ breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722 · cited 1×
“These data are consistent with recent retrospective clinical studies showing that ESR1 mutations in plasma DNA predict relative resistance to AIs but not to fulvestrant (Fribbens et al., 2016; Schiavon et al., 2015; Spoerke et al., 2016).”
Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11579 · Cited by 309 · cited 1×
“These data are consistent with recent retrospective clinical studies showing that ESR1 mutations in plasma DNA predict relative resistance to AIs but not to fulvestrant (Fribbens et al., 2016; Schiavon et al., 2015; Spoerke et al., 2016).”
Self-citationEllis, M. J., Llombart-Cussac, A., Feltl, D., Dewar, J. A., Jasiówka, M., Hewson, N., Rukazenkov, Y., & Robertson, J. F. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5831 · Cited by 238 · cited 1×
“Though fulvestrant has served as an important proof of concept for the SERD approach [see also (Ellis et al., 2015)], it is limited by its poor pharmaceutical properties, which necessitates administration by intramuscular injection and limits the applied dose, exposure, and receptor engagement…”
NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Nettles, K. W., Bruning, J. B., Gil, G., Nowak, J., Sharma, S. K., Hahm, J. B., Kulp, K., Hochberg, R. B., Zhou, H., Katzenellenbogen, J. A., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.76 · Cited by 159 · cited 2×
“Structural studies and molecular dynamics simulations of ER mutants have demonstrated that the Y537S and D538G substitutions shift ER, and particularly helix 12 (H12), into a conformation that resembles an active/liganded ER wild-type conformation, providing a molecular explanation for the constitutive activity of the…”
Cited by
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Self-citationPatel, H. K., & Bihani, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 499
ESR1 mutations in breast cancer
Dustin, D., Gu, G., & Fuqua, S. A. W. (2019) · Cancer · doi:10.1002/cncr.32345 · Cited by 306
Hu, J., Hu, B., Wang, M., Xu, F., Miao, B., Yang, C.-Y., Wang, M., Liu, Z., Hayes, D. F., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01572 · Cited by 268
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
Dragovich, P. S., Adhikari, P., Blake, R. A., Blaquiere, N., Chen, J., Cheng, Y.-X., den Besten, W., Han, J., Hartman, S. J., He, J., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126907 · Cited by 120
Self-citation
Metadata
- Authors
- Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., Grillot, K., Moon, M., Prudente, R., Bischoff, E., Lee, K.-J., Bonnefous, C., Douglas, K. L., Julien, J. D., Nagasawa, J. Y., Aparicio, A., Kaufman, J., Haley, B., Giltnane, J. M., Wertz, I. E., Lackner, M. R., Nannini, M. A., Sampath, D., Schwarz, L., Manning, H. C., Tantawy, M. N., Arteaga, C. L., Heyman, R. A., Rix, P. J., Friedman, L., Smith, N. D., Metcalfe, C., & Hager, J. H.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2016-07-13
- Volume
- 5
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W2468302041
- Cited by
- 118
- References
- 6
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. https://app.cochat.ai/papers/10.7554/elife.15828
- The paper
- Joseph, J. D., Darimont, B., Zhou, W., Arrazate, A., Young, A., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., Kategaya, L., Govek, S. P., Lai, A. G., Kahraman, M., Brigham, D., Sensintaffar, J., Lu, N., Shao, G., Qian, J., . . . Hager, J. H. (2016). The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. eLife. https://doi.org/10.7554/elife.15828
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.